Perseon Announces New Data for MicroThermX(R) in the Treatment of Large Liver Metastases From Colorectal Cancer and Large Hep...
September 21 2015 - 8:46PM
Perseon Corporation (Nasdaq:PRSN) ("Perseon" or the "Company")
today announced that data supporting the use of the company's
cutting edge microwave ablation technology, MicroThermX, was
presented at the 38th Congress of Italian Society of Oncological
Surgery (SICO) in Naples, Italy from September 9 – 12, 2015. The
data included two posters, which looked at the use of multiple
antennas in the treatment of large liver metastases from colorectal
cancer and large hepatocellular carcinoma.
"These studies are just two examples that physicians are
recognizing the unique properties of MicroThermX's Synchronous Wave
Alignment Technology in the treatment of tumors, especially large
tumors where energy ablation was previously viewed as ineffective,"
said Brian Meltzer, M.D., Chief Medical Officer and Vice President
of Business Development. "These data reinforce MicroThermX as a
safe and efficacious treatment option with low complication rates
and the potential to reduce costly surgical resections of
cancer."
- Ablation of Large Liver Metastases from Colorectal
Cancer Using Synchronous Insertion of Multiple Microwave
Antennas evaluated the use of percutaneous energy ablation
for the treatment of large (> 3 cm) colorectal cancer metastases
(CRCmets) of the liver. Findings of this study show that there was
a low complication rate with treatments and a high rate of complete
necrosis. Complete response was shown in 92 percent (11/12) of
patients treated with CRCmets.
- Ablation of Large Hepatocellular Carcinoma (HCC) Using
a New Multiple Antenna Microwave Device: Case Series
evaluated the use of MicroThermX to achieve large volumes of
necrosis in (HCC) by synchronous insertion and activation of
multiple microwave antennas. Results showed that MicroThermX used
in the treatment of (HCC) was safe and efficacious, with complete
necrosis in 80 percent of HCC cases (8/10).
These data come at a time when Perseon continues to push for
clinical results to reflect the safety and efficacy of microwave
ablation, and to show the health economic advantages of using
multiple, synchronized wave antennas at the time of the initial
procedure.
About Perseon
Corporation
Perseon Corporation invests its resources in fighting
humanity's worst disease – cancer. Perseon's people are
dedicated to finding innovative technologies and means to deliver
energy ablation solutions to healthcare providers and patients
around the world. MicroThermX treats soft tissue tumors with
precision-focused energy, expanding the options and broadening the
opportunities for cancer treatment.
About MicroThermX
Perseon's energy ablation system, MicroThermX, has been
developed as a stand-alone therapy that employs precision-guided
microwave energy to ablate (burn) and destroy soft
tissue. Perseon has developed extensive intellectual
property and has established distribution in the United
States, Europe and Asia.
Treatment sites include tumor ablation of the liver, kidney,
brain, bone, lung, and other soft-tissue locations.
Forward-Looking Statements
Statements contained in this press release that are not
historical facts, including statements relating to our focus on
microwave ablation to create stockholder value and pursuit of our
strategic plans are forward-looking statements, as defined in the
Private Securities Litigation Reform Act of 1995. All
forward-looking statements are subject to risks and uncertainties,
including the risk that for a variety of reasons we may not be able
to execute on our strategic plans, and other risks and
uncertainties detailed in the Company's filings with
the Securities and Exchange Commission. These forward-looking
statements speak only as of the date on which such statements are
made, and the Company undertakes no obligation to update such
statements to reflect events or circumstances arising after such
date, except as required by law.
CONTACT: Jennifer R. Hoglin
Vice President of Global Marketing
Phone: (801) 972-5555
Email: jhoglin@perseonmedical.com